文献速递其他结缔组织病

系统性硬化症中的抗细胞致死膨胀毒素抗体:与胃肠道疾病及免疫失调的关联

Anti-cytolethal distending toxin antibodies in systemic sclerosis: associations with gastrointestinal disease and immune dysregulation.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

在130例富含胃肠道疾病的系统性硬化症(SSc)患者中,18%(23/130)检出抗细胞致死膨胀毒素(CDT)抗体;该抗体与抗U11/U12(RNPC3)、抗U1RNP及抗拓扑异构酶-1抗体显著相关,且UCLA GIT土壤样评分更高,抗体滴度随时间无显著变化。

要点

  • 18%(23/130)SSc患者检出抗CDT抗体,与抗U11/U12(RNPC3)、抗U1RNP及抗拓扑异构酶-1抗体显著相关。
  • 抗CDT阳性患者UCLA GIT土壤样评分中位数1(1-2)vs 阴性0(0-2),P=0.037。
  • 抗CDT滴度随时间无显著变化。

核心结论

  • 抗CDT抗体可能作为感染后自身免疫的标志物,并与与严重、进展性胃肠道疾病相关的SSc自身抗体强烈相关。

研究设计与样本

  • 对130例富含胃肠道疾病的SSc患者血清采用ELISA筛查抗CDT抗体,比较有无抗CDT抗体患者的临床特征、UCLA GIT 2.0评估症状及自身抗体谱,并用线性混合效应模型评估抗体滴度随时间变化及与纵向UCLA GIT 2.0评分的相关性。

主要发现

  • 抗CDT抗体在18%(23/130)的SSc患者中检出。
  • 抗CDT抗体阳性患者更常有显著胃肠道疾病(87% vs 71%;P=0.19),但未达统计学显著。
  • 抗CDT抗体阳性患者更常有抗U11/U12(RNPC3)抗体(35% vs 4%;P<0.001)、抗U1RNP抗体(26% vs 8%;P=0.018)和抗拓扑异构酶-1抗体(30% vs 12%;P=0.044)。
  • 抗CDT阳性患者UCLA GIT土壤样评分显著更高[中位数(四分位距)1(1-2)vs 0(0-2);P=0.037]。
  • 多变量分析中,抗CDT抗体与抗U11/U12(RNPC3)[OR 19.0(95%CI:4.3,83.4);P≤0.001]、抗U1RNP抗体[OR 7.2(95%CI:1.9,27.9);P=0.004]及抗拓扑异构酶-1抗体[OR 4.7(95%CI:1.3,16.8);P=0.019]仍显著相关,即使调整混杂因素后。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-cytolethal distending toxin (CDT) antibodies may serve as biomarkers for post-infectious autoimmunity and aid clinical risk stratification. We aimed to determine the prevalence of anti-CDT antibodies in a large, well-characterized cohort of systemic sclerosis (SSc) patients and examine associations with gastrointestinal (GI) and extraintestinal clinical features and SSc-related antibodies. METHODS: Sera from 130 SSc patients enriched for GI disease were screened for anti-CDT antibodies by ELISA. Clinical features, UCLA GIT 2.0-assessed symptoms and autoantibody profiles were compared between patients with and without anti-CDT antibodies. Linear mixed-effects models evaluated whether anti-CDT titres changed over time and correlated with longitudinal UCLA GIT 2.0 scores. RESULTS: Anti-CDT antibodies were detected in 18% (23/130) of SSc patients. Patients with anti-CDT antibodies more frequently had significant GI disease (87% vs 71%; P = 0.19) and were significantly more likely to have antibodies to U11/U12 (RNPC3) (35% vs 4%; P < 0.001), U1RNP (26% vs 8%; P = 0.018) and topoisomerase-1 (30% vs 12%; P = 0.044). UCLA GIT Soilage scores were significantly higher among anti-CDT positive patients [median (interquartile range) 1 (1-2) vs 0 (0-2); P = 0.037]. In multivariable analyses, anti-CDT antibodies remained significantly associated with anti-U11/U12 (RNPC3) [odds ratio (OR) 19.0 (95% CI: 4.3, 83.4); P ≤ 0.001], anti-U1RNP antibodies [OR 7.2 (95% CI: 1.9, 27.9); P = 0.004] and anti-topoisomerase-1 antibodies [OR 4.7 (95% CI: 1.3, 16.8); P = 0.019], even after adjusting for confounders. Anti-CDT titres did not change significantly over time. CONCLUSIONS: Anti-CDT antibodies may serve as markers of post-infectious autoimmunity and strongly associate with SSc-autoantibodies linked to severe, progressive GI disease. Understanding the connection between anti-CDT antibodies and SSc-specific autoimmunity may provide insight into disease pathogenesis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Di Ciommo FR, Casciola-Rosen L, Ayla AY, et al. Anti-cytolethal distending toxin antibodies in systemic sclerosis: associations with gastrointestinal disease and immune dysregulation. Rheumatology (Oxford). 2025. PMID: 40637696. doi:10.1093/rheumatology/keaf376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。